CHARM Alternative trial
Last reviewed 02/2023
The CHARM-Alternative trial recruited 2028 ACE inhibitor-intolerant patients with heart failure due to left ventricular dysfunction. The patients were randomised to either candesartan or placebo.
Treatment with candesartan (an angiotensin receptor antagonist) gave clear reductions in mortality and hospital admissions.
Reference: